DiscoverNEI Podcast
NEI Podcast
Claim Ownership

NEI Podcast

Author: Neuroscience Education Institute

Subscribed: 799Played: 13,967
Share

Description

The Neuroscience Education Institute (NEI) is committed to help raise the standard of mental health by providing imaginative medical education that focuses on the highest level of learning. Each episode offers an opportunity to learn about current issues in psychiatry from key opinion leaders in the medical field. NEI's Podcast would be of value to anyone with an interest in neuropsychiatric diseases and psychopharmacology.
277 Episodes
Reverse
PsychopharmaPearls is NEI's focused podcast series highlighting the clinical insights that can sharpen your prescribing decisions. In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal esketamine for patients with difficult-to-treat depression. They unpack the differences that truly matter in practice—from patient selection and monitoring to access, cost, and common missteps. Tune in for practical pearls you can immediately apply to select the right treatment for the right patient.  Lisa Harding, MD is a board-certified psychiatrist and nationally recognized depression specialist with deep expertise in interventional psychiatry. She has performed more than 4,000 procedures, including electroconvulsive therapy (ECT), intravenous ketamine, intranasal esketamine, and transcranial magnetic stimulation (TMS). Dr. Harding is known for her thoughtful approach to complex, treatment-resistant depression, integrating advanced somatic therapies, psychopharmacology, and psychotherapy. She serves as an Assistant Clinical Professor of Psychiatry at Yale University in New Haven, Connecticut.  Andrew J. Cutler, MD is a leading psychiatrist, psychopharmacology expert, and clinical researcher with decades of experience in CNS drug development. As Chief Medical Officer of Neuroscience Education Institute and EMA Wellness, he brings frontline clinical insight together with deep knowledge of the evidence base. Dr. Cutler is widely recognized for translating research into practical guidance for everyday practice and serves as a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Sanacora G et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017;74(4):399-405. doi:10.1001/jamapsychiatry.2017.0080  McIntyre RS et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry 2021;178(5):383-399. doi:10.1176/appi.ajp.2020.20081251    Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring    Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter
In this episode, Dr. Andy Cutler talks with Dr. Tim Wilens about enduring myths surrounding ADHD diagnosis and treatment, beginning with why misconceptions about overdiagnosis and misuse continue to shape clinical hesitation. They explore common misunderstandings about ADHD medications—including stimulants versus non-stimulants, concerns about diversion, personality changes, and long-term safety—and contrast stigma-driven narratives with the clinical evidence. The conversation equips clinicians with practical, evidence-based strategies to address patient fears, counter misinformation, and make thoughtful, individualized treatment decisions.  Timothy Wilens, MD, is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital. He is the MGH Trustees Chair in Addiction Medicine and a professor of psychiatry at Harvard Medical School. Dr. Wilens' research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders, embedded health care models, and the pharmacotherapy of ADHD across the lifespan.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter
In this episode, Dr. Andy Cutler speaks with Dr. Jonathan Meyer to dispel common myths about antipsychotic treatment, from concerns about sedation, personality change, and brain effects to misunderstandings about safety, long-acting injectables, and clozapine. The discussion focuses on what the evidence actually shows about efficacy, risk, and recovery, and how clinicians can communicate more clearly and confidently with patients and families.  Jonathan Meyer, MD, DLFAPA, is a Voluntary Clinical Professor of Psychiatry at the University of California, San Diego. He serves as a Senior Academic Advisor to the California Department of State Hospitals, is a psychopharmacology consultant to the first episode psychosis program at Balboa Naval Medical Center, and has published extensively on psychopharmacology, including co-authoring The Clozapine Handbook, The Clinical Use of Antipsychotic Plasma Levels, and The Lithium Handbook with Dr. Stephen Stahl.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this episode, Dr. Andy Cutler and Dr. Jeff Strawn unpack common misconceptions that complicate real-world use of antidepressants. They review evidence on efficacy, suicidality risk, mechanisms, and early side effects, and discuss how to navigate hesitancy and misinformation. The conversation also addresses when to start medication, how to balance caution with timely intervention in youth, and practical ways to strengthen trust and therapeutic alliance.  Jeffrey R. Strawn, MD, FAACAP, is a Professor of Psychiatry, Pediatrics, and Clinical & Translational Pharmacology at the University of Cincinnati (UC) in Cincinnati, Ohio. He is the Director of the UC Anxiety Disorders Research Program and the Associate Vice Chair of Research in the Department of Psychiatry & Behavioral Neuroscience at UC.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Zhang K et al. Functional connectivity predicting transdiagnostic treatment outcomes in internalizing psychopathologies. JAMA Netw Open 2025;8(9):e2530008. doi: 10.1001/jamanetworkopen.2025.30008  Lagerberg T et al. Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study. Neuropsychopharmacology 2022;47(4):817-23. doi: 10.1038/s41386-021-01179-z  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
As 2025 comes to an end, we revisit our most downloaded episode of the year. Join Dr. Andy Cutler and Dr. Carla Sharp as they explore the current conceptualization of borderline personality disorder (BPD), including diagnostic challenges, evidence-based treatments, and strategies to reduce stigma by framing BPD as a treatable condition. The conversation also highlights recent updates to the APA's BPD guidelines and what they mean for clinical practice.  Carla Sharp, PhD is a distinguished clinical psychologist specializing in developmental psychopathology, particularly borderline personality disorder (BPD). She is a professor in the Clinical Psychology Doctoral Program and serves as the Associate Dean for Faculty and Research at the University of Houston. Additionally, she directs both the Adolescent Diagnosis, Assessment, Prevention, and Treatment Center and the Developmental Psychopathology Lab at the university.    Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube Instagram: https://nei.global/instagram LinkedIn: https://nei.global/linkedin Facebook: https://nei.global/facebook X: https://nei.global/twitter
Join Drs. Andy Cutler and Roger McIntyre as they discuss the most significant advancements in psychopharmacology over the past year. Their conversation highlights groundbreaking developments and innovations in the field of psychiatry.   Roger McIntyre, MD, FRCPC, is a globally recognized psychiatrist and psychopharmacologist who holds pivotal roles in academia, research, and leadership. His research primarily focuses on the phenomenology, neurobiology, and development of novel therapeutics for mood disorders. Dr. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Thanarajah ES et al. Soft drink consumption and depression mediated by gut microbiome alterations. JAMA Psychiatry 2025;82(11):1095–1102. doi:10.1001/jamapsychiatry.2025.2579  Durgam S et al. Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. J Clin Psychiatry 2025;86(4):25m15848. doi: 10.4088/JCP.25m15848  Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2025;82(4):395–405. doi: 10.1001/jamapsychiatry.2024.4789  Aron L et al. Lithium deficiency and the onset of Alzheimer's disease. Nature 2025;645:712–21. doi: 10.1038/s41586-025-09335-x  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this CME episode, Dr. Andy Cutler talks with Drs. Stephen Stahl and Roger McIntyre about recognizing and managing complex depression, particularly major depressive episodes with mixed or anxious features. They discuss how these specifiers affect diagnosis, symptom severity, and treatment response, and explore evidence-based strategies for optimizing outcomes through individualized and adjunctive approaches. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e270-cme Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this CME episode, Dr. Andy Cutler and Dr. Christoph Correll discuss the complexities of managing bipolar disorder, with a focus on recognizing and treating mixed states. They address overlapping manic and depressive symptoms, comorbidities, and the importance of shared decision-making, family involvement, and patient education. The conversation also explores strategies to improve adherence, the impact of substance use, and the value of a collaborative, individualized approach to long-term stability and recovery. Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e269-cme Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
This episode includes extended Q&A sessions that address your unanswered questions from the following presentations delivered at the 2025 Fall Congress in Colorado Springs, Colorado:  (00:22) A Discussion of Substance: Supporting Meaningful Improvements in the Lives of Patients Struggling With Substance Use Disorders by Brittany Albright, MD, MPH and Hara Oyedeji, DNP, PMHNP-BC (Q&A with Dr. Albright)  (34:08) Nightmares and Brainscapes: Emerging Therapeutic Avenues in the Treatment of PTSD by Lori Davis, MD and Andrew Cutler, MD (Q&A with Dr. Davis)  (47:43) Sex, Pudge, and Eyes That Close: Strategies to Address Common Psychotropic–Induced Tolerability Issues by Leslie Citrome, MD, MPH and Andrew Cutler, MD (Q&A with Dr. Citrome)   (55:00) When Less Is More: Strategies for Deprescribing Psychotropic Medications by Jeffrey Strawn, MD and Kari Franson, PharmD, PhD, BCPP (Q&A with Dr. Strawn)  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast – available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In recognition of Stress Awareness Week, the NEI Podcast revisits a vital conversation with Dr. Joan Striebel about the syndrome of catatonia—a condition that can emerge from profound psychological or physiological stress. Dr. Andy Cutler and Dr. Striebel discuss its dynamic presentation, the importance of treating underlying causes, and why clinicians should maintain a high index of suspicion when evaluating complex or unexplained psychiatric symptoms. This re-release highlights key insights to help clinicians recognize and manage catatonia more effectively in practice.  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this episode, Dr. Andy Cutler talks with Dr. Ryan Sultán about the evolving landscape of ADHD—why diagnoses and prescriptions have risen across age groups, what recent prescribing data reveal, and how these trends align with real-world clinical experience. They explore how ADHD medications affect not just symptoms but broader outcomes like school, work, and safety, while also addressing concerns about overdiagnosis, misuse, and disparities in access to care.   Dr. Ryan Sultan is a board-certified adult and child psychiatrist specializing in attention-deficit/hyperactivity disorder (ADHD) and assistant professor at Columbia University Irving Medical Center and the New York State Psychiatric Institute. He is the Medical Director of NYC-based Integrative Psychiatry, where he assesses and treats patients using a combination of psychological, social, environmental, and pharmacological modalities. Integrative Psychiatry also provides ADHD treatment in Miami. As an ADHD psychiatrist, he conducts extensive ADHD research with a focus on using big data to improve ADHD treatment in real world settings, advocating for non-pharmacological interventions such as cognitive behavioral therapy (CBT) for ADHD, coaching, and digital tools as a foundational treatment that precedes or supplements medication. He approaches ADHD treatment with a nuanced understanding of the current misuse and overdiagnosis crisis, and addresses this issue through careful assessment and monitoring.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this episode, Dr. Andy Cutler interviews Dr. Peter Weiden about when and how to switch antipsychotics in schizophrenia, tackling both the pitfalls and opportunities clinicians face in practice. They also explore how xanomeline–trospium has opened the door to treatments beyond dopamine and what this shift means for the future of care.  Peter J. Weiden, MD, is a psychiatrist and internationally recognized expert in the pharmacologic treatment of schizophrenia. His research and clinical work have focused on antipsychotic effectiveness, switching strategies, and medication adherence, with a particular emphasis on optimizing long-term outcomes for patients.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this CME episode, Dr. Andy Cutler speaks with Dr. Manpreet Singh, the Robert H. Putnam Endowed Chair in Bipolar Research and Treatment at UC Davis, about the challenges of diagnosing and treating pediatric bipolar disorder. Dr. Singh shares evidence-based strategies for treatment, management of bipolar depression and medication side effects, and best practices for long-term care and transitioning youth into adult services.  NEI Members can earn CME/CE by participating in this activity here: https://nei.global/e264-cme Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter       
In this episode, Dr. Andy Cutler interviews Dr. Dan Singley about the unique challenges men face in recognizing, expressing, and seeking care for their mental health. They explore how norms around masculinity influence help-seeking behavior and contribute to men's heightened risk of suicide. The conversation also highlights the underrecognized issue of paternal perinatal depression, its impact on family dynamics, and strategies clinicians can use to better screen, engage, and support new fathers.  Dr. Daniel Singley, PhD, is a clinical psychologist and expert in men's mental health, with a particular focus on the transition to fatherhood and perinatal mental health for men. He is the founder and director of the Center for Men's Excellence in San Diego, where he provides therapy, consultation, and training centered on men's psychological development and gender-sensitive care.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  The Center for Men's Excellence – menexcel.com  Society for the Psychology of Men and Masculinities – division51.net  Postpartum Support International – postpartum.net  Man Therapy – mantherapy.org  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this episode, Dr. Andy Cutler interviews Dr. Roger McIntyre about the growing recognition of Long COVID and its wide-ranging neuropsychiatric manifestations. They discuss the role of neuroinflammation in its pathophysiology, the impact of these symptoms on patients' daily functioning, and both current and emerging treatment approaches.  Dr. Roger McIntyre is a globally recognized psychiatrist and psychopharmacologist who holds pivotal roles in academia, research, and leadership. His research primarily focuses on the phenomenology, neurobiology, and development of novel therapeutics for mood disorders. Dr. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this episode, Dr. Andy Cutler interviews Dr. Pamela Wall about the complex intersection of PTSD and mild traumatic brain injury (mTBI) in veterans. They explore how military culture influences the experience and treatment of trauma, the challenges of distinguishing overlapping symptoms, and evidence-based strategies for assessment and intervention. Tune in for practical insights, clinical pearls, and resource recommendations for improving care in this uniquely vulnerable population.  Pamela Wall, PhD, PMHNP-BC is an associate professor in the College of Nursing at Rosalind Franklin University and maintains a clinical practice at a neuropsychiatric clinic in Fairfax, VA. She has extensive experience working with adult psychiatric mental health populations, and her research has focused on PTSD, mTBI, and sleep disorders in deployed military service members. Dr. Wall served 20 years on active duty as a Nurse Corps Officer in the United States Navy.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Center for Deployment Psychology   National Center for PTSD  Traumatic Brain Injury Center of Excellence    Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on: YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this episode, Dr. Andy Cutler interviews Dr. Steven Chan about the evolving role of artificial intelligence (AI) in psychiatry. They explore practical, real-world applications of AI in clinical settings, highlighting both the benefits and limitations of current technologies. The conversation also looks ahead to the future of AI in mental health care as advancements continue to accelerate.  Steven Chan, MD, MBA, is a clinical informaticist and psychiatrist, as well as a Clinical Assistant Professor at the Stanford University School of Medicine. He is also the Chief Technology Officer and co-founder of AsyncHealth. Dr. Chan's research focuses on telepsychiatry and digital mental health.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Resources  Readiness Evaluation for Artificial Intelligence (READI)  APA App Advisor  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this episode, Dr. Andy Cutler sits down with Dr. Debbi Morrissette, Senior Director of Educational Development at NEI, to explore the magic behind NEI Congress. Tune in as they talk about the unique elements of NEI Congress that bring the visual language of psychopharmacology to life!  Are you ready to step up your clinical game? Join us at the 2025 NEI Fall Congress, Nov. 6–9 in Colorado Springs (or online via simulcast)! Explore a comprehensive program of psychopharmacology essentials: treatments, side effects, drug interactions, and more — all taught by top-tier faculty.  Special Offer for NEI Podcast Listeners: Register now and save $50 off your registration with code POD25FALL   Register today at https://nei.global/fall  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter
In this episode, Dr. Andy Cutler and Dr. Jeffrey Strawn explore the complexities of obsessive-compulsive disorder (OCD). Join the conversation as they discuss how OCD presents across different patients, evidence-based treatment approaches, and the critical role clinicians play in helping individuals manage symptoms and work toward remission.  Jeffrey R. Strawn, MD, FAACAP is a Professor of Psychiatry, Pediatrics, and Clinical & Translational Pharmacology at the University of Cincinnati (UC) in Cincinnati, Ohio. He is the Director of the UC Anxiety Disorders Research Program and the Associate Vice Chair of Research in the Department of Psychiatry & Behavioral Neuroscience at UC.  Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
In this CME podcast episode, Dr. Andrew Cutler interviews Dr. Phillip Coffin, Director of the Center on Substance Use and Health in San Francisco, CA, about the management of stimulant use disorders. They explore the challenges of treatment and highlight the importance of harm reduction strategies to enhance patients' quality of life.   NEI Members can earn CME/CE by participating in this activity here: https://nei.global/e257-cme  Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast  Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp   Stay updated with email alerts and join our conversations on social. Follow us on:  YouTube: https://nei.global/youtube  Instagram: https://nei.global/instagram  LinkedIn: https://nei.global/linkedin  Facebook: https://nei.global/facebook  X: https://nei.global/twitter 
loading
Comments (2)

Reaction Last

From comprehensive psychiatric and metabolic care to cutting-edge aesthetic treatments, https://www.horizonpeakhealth.com/ deliver ICU-grade expertise for true wellness and confidence

Feb 23rd
Reply

Tooy Oz

Too many OKs by the interviewer

Apr 11th
Reply
loading